Floatz logo

Enzalutamide

B-cell Lymphoma Recurrent

Universität MünsterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the B-cell Lymphoma Recurrent cohort.

Asset / SponsorPhaseRating
Axicabtagene Ciloleucel
Lyell Immunopharma, Inc.
Phase 4BBB
yy-20394
Jiangsu HengRui Medicine Co., Ltd.
Phase 2B
Recombinant Humanized Monoclonal Antibody Mil62
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2CCC
Abiraterone Acetate
Universität Münster
Phase 2CCC
Docetaxel
Universität Münster
Phase 2CCC

View all 9 →

Same molecule, other indications

Enzalutamide is also rated in:

Metastatic Castration Resistant Prostate CancerDormant
BBB
Indicative ·
77 / 100
View asset →
prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
castration-resistant prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →